Monthly Archives: August 2019
Medications and renal failure can go hand in hand. This is of course if we are talking about the right medications. There are numerous medications that can cause an acute renal failure situation, but many times in practice, it is due to a cumulative risk. Here’s a case scenario to ponder… An 88-year-old female is […]
Read More
As I’m working on 2020 updates for all of our board certification study material, I couldn’t help but recognize that I did not have a dedicated lecture on pharmacogenomics. Below I discuss how genetic alterations in CYP2D6 activity can affect two commonly used medications. CYP2D6 is a well known metabolic enzyme that causes structural changes […]
Read More
A 62-year-old male had a heart attack about 9 months ago. He was stented and placed on both aspirin 81 mg daily and clopidogrel 75 mg daily. He presents today to the emergency department and is diagnosed with a STEMI. His wife is wondering why the medications used to prevent this from happening didn’t work. […]
Read More
Glucagon can be a lifesaver, literally. Glucagon’s primary use is in the setting of severe hypoglycemia. Glucagon works by increasing cyclic AMP which causes glycogenolysis and gluconeogenesis. This ultimately leads to an increase in glucose in the blood and helps manage a hypoglycemic state. Here are some clinical pearls that are important to glucagon’s use. […]
Read More
Enzyme inducers most frequently reduce the concentrations of other drugs. This can ultimately lead to treatment failure. In rare situations (i.e. prodrugs), starting an enzyme inducer can potentially raise concentrations of the active metabolite and increase the risk for toxicity. Throughout my pharmacy career, I’ve been tested on various enzyme inducers. Here’s my top 5. […]
Read More